Department of Anesthesiology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
PLoS One. 2018 Apr 5;13(4):e0195528. doi: 10.1371/journal.pone.0195528. eCollection 2018.
Right ventricular (RV) dysfunction following left ventricular (LV) failure is associated with poor prognosis. RV remodeling is thought initiated by the increase in the afterload of RV due to secondary pulmonary hypertension (PH) to impaired LV function; however, RV molecular changes might occur in earlier stages of the disease. cGMP (cyclic guanosine monophosphate)-phosphodiesterase 5 (PDE5) inhibitors, widely used to treat PH through their pulmonary vasorelaxation properties, have shown direct cardiac benefits, but their impacts on the RV in LV diseases are not fully determined. Here we show that RV molecular alterations occur early in the absence of RV hemodynamic changes during LV pressure-overload and are ameliorated by PDE5 inhibition. Two-day moderate LV pressure-overload (transverse aortic constriction) neither altered RV pressure/ function nor RV weight in mice, while it induced only mild LV hypertrophy. Importantly, pathological molecular features were already induced in the RV free wall myocardium, including up-regulation of gene markers for hypertrophy and inflammation, and activation of extracellular signal-regulated kinase (ERK) and calcineurin. Concomitant PDE5 inhibition (sildenafil) prevented induction of such pathological genes and activation of ERK and calcineurin in the RV as well as in the LV. Importantly, dexamethasone also prevented these RV molecular changes, similarly to sildenafil treatment. These results suggest the contributory role of inflammation to the early pathological interventricular interaction between RV and LV. The current study provides the first evidence for the novel early molecular cross-talk between RV and LV, preceding RV hemodynamic changes in LV disease, and supports the therapeutic strategy of enhancing cGMP signaling pathway to treat heart diseases.
左心室(LV)衰竭后右心室(RV)功能障碍与预后不良相关。RV 重构被认为是由继发性肺动脉高压(PH)引起的 RV 后负荷增加导致 LV 功能受损而引发的;然而,RV 分子变化可能发生在疾病的早期阶段。广泛用于通过其肺血管舒张特性治疗 PH 的 cGMP(环鸟苷单磷酸)-磷酸二酯酶 5(PDE5)抑制剂,已显示出直接的心脏益处,但它们对 LV 疾病中 RV 的影响尚未完全确定。在这里,我们表明在 LV 压力超负荷期间 RV 血流动力学变化之前,RV 分子改变很早就发生了,并且 PDE5 抑制可改善这些改变。两天的中度 LV 压力超负荷(主动脉缩窄)既没有改变 RV 的压力/功能,也没有改变 RV 的重量,而只是引起了轻度的 LV 肥大。重要的是,病理分子特征已经在 RV 游离壁心肌中诱导,包括肥大和炎症的基因标记上调,以及细胞外信号调节激酶(ERK)和钙调神经磷酸酶的激活。同时抑制 PDE5(西地那非)可防止 RV 以及 LV 中这些病理性基因的诱导以及 ERK 和钙调神经磷酸酶的激活。重要的是,地塞米松也可防止 RV 分子的这些变化,类似于西地那非的治疗作用。这些结果表明炎症在 RV 和 LV 之间早期病理性的室间隔相互作用中起作用。本研究首次提供了在 LV 疾病中 RV 血流动力学变化之前,RV 和 LV 之间早期分子交叉对话的新证据,并支持增强 cGMP 信号通路治疗心脏病的治疗策略。